Pathogenetic therapy of heart failure: beta-adrenoblockers
https://doi.org/10.15829/1728-8800-2012-6-68-70
Abstract
The paper discusses key aspects of the chronic heart failure (CHF) pathogenesis, which justify the use of β-adrenoblockers (β-AB) in the treatment of CHF. The authors present the clinical and experimental evidence confirming the effectiveness of these agents in CHF patients. Dose titration and the use of β-AB in various clinical groups are also discussed.
About the Authors
O. Yu. Shayduk
N. I. Pirogov Russian National Medical University, Moscow
Russian Federation
Russian Federation
E. O. Taratukhin
N. I. Pirogov Russian National Medical University, Moscow
Russian Federation
Russian Federation
References
1. Libby P, Bonow L, Zipes D, et al. Braunwald’s Heart Disease. 8th ed / Elsevier. - 2008
2. Floras JS. Alterations in the sympathetic and parasympathetic nervous system in Heart Failure. In Mann DL [ed]: Heart Failure: A companion to Braunwald’s Heart Disease. Elsevier 2004.
3. Katzung B, Masters S, Trevor A. Basic and Clinical Pharmacology. 12th ed. Lange 2011.
4. National Guidelines for Heart Failure. 3rd ed. Heart Failure 2010; 1(11). Russian (Национальные рекомендации ВНОК и ОССН (третий пересмотр). Серд недостат 2010; 1(11).
5. Allen LA, Stevenson LW, Grady KL, et al. AHA Scientific Statement: Decision Making in Advanced Heart Failure. Circulation 2012; 125: 1928-52.
6. Dekleva M, Déngen HD, Goeblich G, et al. Beta-blockers therapy is associated with imroved left ventricular systolic function and sustained exercise capacity in elderly patients with HF - CIBIS-ELD substudy. Aging Clin Exp Res 2012; Nov 12 (PMID 23147869).
7. Cowie MR. Recent developments in the management of heat failure. Practitioner 2012; 256(6): 25-9.
8. Stankovic I, Nescovic AN, Putnikovic B, et al. Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure. Int J Cardiol 2012; Jun 21 (PMID 22726401).
9. Ong HT, Ong LM, Kow FP. Beta-blockers for heart failure: an evidence based review answering practical therapeutic questions. Med J Malaysia 2012; 67(1): 7-11.
10. Sarraf M, Francis GS. Beta-blockers in stage B: a precursor of heart failure. Heart Fail Clin 2012; 8(4): 237-45.
11. Rengo G, Lymperopoulous A, Zincarelli C, et al. Blockade of beta-adrenoreceptors restores the GRK2-mediated adrenal alpha-2-adrenoreceptorcatecholamine production axis in heart failure. Br J Pharmacol 2012; 166(8): 2430-40.
12. He YM, Yang XJ, Zhao X, et al. Beta-blockers in heart failure: benefits of beta-blockers according to varying male proportions of study patients. Clin Cardiol 2012; 35(8): 505-11.
13. Wai B, Kearney LG, Hare DL, et al. Beta-blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol 2012; 14: 11-4.
14. Spoladore R, Fragasso G, Perseghin G, et al. Beneficial effects of betablockers on left ventricular function and cellular energy reserve in patinets with heart failure. Fundam Clin Pharmacol 2012; Feb 9.
15. de Man FS, Handoko ML, van Ballegoij JJ, et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 2012; 5: 97-105.
16. Gelbrich G, Eldermann F, Inkrot S et al. Is target dose the treatment target? Int J Cardiol 2012; 155(1): 160-6.
17. Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with CHF and COPD: a randomized trial. Respir Med 2011; 105: 44-9.
18. Duengen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Gail 2011; 13(6): 670-80.
Review
For citations:
Shayduk O.Yu., Taratukhin E.O. Pathogenetic therapy of heart failure: beta-adrenoblockers. Cardiovascular Therapy and Prevention. 2012;11(6):68-70. (In Russ.) https://doi.org/10.15829/1728-8800-2012-6-68-70
Views:
1342
Email this article 
